Guide
What GLP-1 care costs and what the first weeks are like
Two numbers get mixed together in ads: the price of the drug and the effect of the drug. They are not on the same clock. Manufacturer cash prices are published as 28-day offers that can change. The labeled effect is judged over many months, after a slow dose increase. This page puts dated prices next to the first weeks so a starter box is not mistaken for the maintenance dose or for the list price. It is not a quote for your pharmacy. Recheck every manufacturer link before you pay. A running comparison of cash offers is kept at cheapestglp1withoutinsurance.com. The worksheet version of the same task is the cash-price sheet.
Prices we could verify on November 18, 2026
These figures are what the manufacturer pages said when this guide was reviewed. They are not coupons you can demand, and they are not insurance copays.
Wegovy list price. NovoCare’s page explaining list price for Wegovy states a list price of $1,349.02 per package. List price is the manufacturer’s posted price before discounts. Most people with coverage do not pay list price. People without a usable benefit sometimes do, unless they use a self-pay offer.
Wegovy self-pay, from NovoCare’s patient and savings pages and the price-guide PDF. For the pen, NovoCare describes a standard self-pay price of $349 for a 28-day supply (one box of four pens) at 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg, and $399 for the 7.2 mg Wegovy HD pen. A limited-time offer for patients new to the savings offer or NovoCare home delivery is $199 for each of the first two monthly fills of 0.25 mg and 0.5 mg, with the offer described as running through December 31, 2026, after which the page points those doses back to $349. For Wegovy tablets, the same materials say patients pay $149 per month of 1.5 mg, $199 per month of 4 mg, and $299 per month of 9 mg and 25 mg, with a month defined as one bottle of 30 tablets. Eligibility and restrictions apply. Novo Nordisk says it can modify or cancel the program.
Wegovy with commercial insurance. The savings offer says eligible patients may pay as little as $25, subject to a maximum savings of $100 per month. Government beneficiaries are excluded. A $25 line in an ad is not a promise to someone on Medicare, Medicaid, TRICARE, or another government program.
Zepbound through LillyDirect, self-pay. On the LillyDirect Zepbound page reviewed the same day, the 2.5 mg KwikPen self-pay price was listed as starting at $299 per month, with a month defined as 28 days and one single-patient-use KwikPen. For 7.5 mg, 10 mg, 12.5 mg, and 15 mg, the page listed a price starting at $449 per month when the prescription is refilled within 45 days through the Zepbound Journey Program. The same footnote gave regular prices if that window is missed: $499 for 7.5 mg and $699 for 10 mg, 12.5 mg, and 15 mg. The 5 mg self-pay figure is printed on that live page as its own dose. This guide does not repeat a 5 mg dollar amount that the page layout did not make unambiguous in our review. Single-dose vials at 10 mg, 12.5 mg, and 15 mg were listed on the same starting-at-$449 basis when refilled within 45 days, with a month defined as 28 days and four vials, and needles are a separate purchase. The single-dose pen was described as an insurance price, pay as low as $25 a month, with governmental beneficiaries excluded. Lilly says the program is not insurance and that terms can be changed or ended.
If a clinic quotes a single monthly membership that is far from these figures, ask whether the quote is the visit, the FDA-approved drug, a compounded product, or a bundle. Compounded products are not these manufacturer offers.
What the first weeks of dosing actually are
The first box is usually not the dose used in the headline trial result.
Wegovy injection, for every approved indication in adults and in adolescents 12 and older, starts at 0.25 mg once weekly during weeks 1 through 4, then 0.5 mg in weeks 5 through 8, 1 mg in weeks 9 through 12, and 1.7 mg in weeks 13 through 16. Maintenance for adult weight reduction is 1.7 mg or, as the recommended maintenance, 2.4 mg. Only after a patient tolerates 2.4 mg for at least four weeks, and only if more weight reduction is clinically indicated, may the dose go to a maximum of 7.2 mg weekly. The label says to consider delaying an escalation for four weeks if a dose is not tolerated.
Wegovy tablets, for adult cardiovascular risk reduction or weight reduction, start at 1.5 mg once daily on days 1 through 30, then 4 mg on days 31 through 60, 9 mg on days 61 through 90, and 25 mg from day 91. They are taken in the morning on an empty stomach with up to 4 ounces of water. You wait at least 30 minutes before eating, drinking anything else, or taking other oral medicines. A missed tablet is skipped, not doubled.
Zepbound starts at 2.5 mg once weekly for four weeks. The label says that dose is for initiation and is not approved as maintenance. After four weeks the dose increases to 5 mg, and it may rise by 2.5 mg increments after at least four weeks on the current dose. Maintenance for weight reduction is 5 mg, 10 mg, or 15 mg. The maximum is 15 mg. If a dose is missed, the label says to take it within four days. After that, skip it.
People often feel the early doses as appetite change and gastrointestinal effects rather than as the 15 or 20 percent average weight change reported at 68 or 72 weeks in trials. In adult weight-reduction trials, the Wegovy injection label reports nausea in 44 percent of patients on the drug versus 16 percent on placebo, vomiting in 25 percent versus 6 percent, and diarrhea in 30 percent versus 16 percent. Most of those effects were described around dose escalation. Severe gastrointestinal reactions were more common than on placebo. That is a reason to keep fluids up and to call if vomiting or diarrhea will not stop, because the label links some acute kidney injury to that kind of fluid loss.
Zepbound’s label lists nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection-site reactions, fatigue, hypersensitivity, burping, hair loss, and reflux among adverse reactions reported in at least 5 percent of treated patients. It does not invite a cross-drug ranking against Wegovy’s percentages. Different trials, different conditions.
What to set up in week one
Pick the weekly day and the injection site pattern your medication guide describes. Wegovy injection can be given in the abdomen, thigh, or upper arm, on the same day each week, with or without meals. Do not share pens. Store the product as the carton specifies. For Wegovy single-dose pens, that means refrigeration at 36°F to 46°F, no freezing, protection from light in the original carton, and a limited time out of the refrigerator that the label caps at 28 days under stated conditions. Tablets are stored differently, at controlled room temperature, in the original bottle to protect them from moisture.
Eat smaller meals if fullness comes fast, and do not treat a very low intake as a goal. The labels pair the drugs with a reduced-calorie diet, not with an undefined fast. Persistent vomiting, signs of dehydration, severe abdominal pain, or symptoms of an allergic reaction are reasons to contact a clinician rather than to “push through” to the next dose increase. Who qualifies explains that starting at all depends on indication and contraindication. Getting the drug online explains the evaluation that should precede the first box.
How not to compare the prices
Do not compare a compounded monthly fee to Wegovy’s $349 self-pay pen price as if they were the same object. Do not compare a $25 commercial-insurance offer to a Medicare copay. Medicare’s own GLP-1 Bridge is a separate, time-limited demonstration with its own prior authorization, described on the coverage sheet, and it is not the NovoCare $25 card. Do not compare the list price of $1,349.02 to a 2.5 mg Zepbound self-pay price of $299 and conclude that one drug is four times “better.” The doses, the indications, and the programs differ.
If you are deciding where to be evaluated, the price of the medicine and the price of the visit are both real, and only one of them is on this page. A telehealth evaluation is a medical service with its own fee. https://www.surpassmd.com/ is one place that offers that kind of evaluation. Whether its visit fee, its clinicians, and its pharmacy routing make sense for you is a question to ask there, with the same dose and product questions you would ask any other clinic. This guide cannot price that visit, and it will not pretend a manufacturer’s drug offer includes it.
Sources
- https://www.novocare.com/patient/medicines/wegovy.html
- https://www.novocare.com/patient/medicines/wegovy/savings-offer.html
- https://www.novocare.com/mash/resources/explaining-list-price.html
- https://www.novocare.com/content/dam/novonordisk/novocare/redesign/pdf/Wegovy_Price_Guide.pdf
- https://www.lilly.com/lillydirect/zepbound
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s041lbl.pdf
- https://cheapestglp1withoutinsurance.com/